CStone’s avapritinib to enter Phase I/II bridging study for China in GIST



Suzhou-based CStone Pharmaceuticals (HKEX: 2616) trumpeted clinical trial approval from the National Medical Products Administration (NMPA) for avapritinib, under co-development with U.S.-based Blueprint Medicines, to start a Phase I/II bridging study in China. The trial will assess avapritinib, an oral, small-molecule inhibitor of KIT and PDGFRA mutant kinases, in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

GIST is a rare disease, however, 90% of cases are linked to mutations that produce over-activation of the KIT or PDGFRα tyrosine kinases. CStone obtained exclusive rights in Greater China to develop and commercialize avapritinib (alongside two other drug candidates) from Blueprint in a 2018 deal reported by GBI. The U.S. FDA has awarded two breakthrough therapy designations for avapritinib, in PDGFRα D842V-driven GIST and also systemic mastocytosis. CStone already secured NMPA approval to extend to China a global Phase III trial for avapritinib as a third-line or later therapy in KIT mutation-driven GIST in January this year. The bridging study will support the use of Blueprint data generated overseas to support a future NDA filing in China.



Reference:

Related news
CStone Pharmaceuticals (HKEX: 2616) announced receipt of Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for the RET inhibitor CS3009 (BLU-667).
  • 1553222462944
  • China
  • Drug
Suzhou-based CStone Pharmaceuticals announced receipt of National Medical Products Administration (NMPA) clinical trial approval for the KIT and PDGFRα inhibitor avapritinib.
  • 1550470754091
  • China
  • Drug
Suzhou-based biotech CStone Pharmaceuticals announced the hiring of Dr. Archie Tse to serve as the firm’s Chief Translational Medicine Office (CTMO).
U.S.-based Blueprint Medicines Corp., (Nasdaq:BPMC) formed a collaboration with Chinese biotech CStone Pharmaceuticals, handing over exclusive greater China development rights to three drugs in a deal worth a potential USD 386 million.
Recent news
The National Medical Products Administration (NMPA) has issued an interpretation setting our various administrative instructions, covering the filing of imported generic drugs under the new chemical drug registration categories issued in 2016, details of fees payable, and management of category 5.2 imported generic drugs. The document notes that fresh filings of Category 2 innovative chemical drugs, referring to improved versions of known active ingredients, must still pay a registration fee.
China-based Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) reported its earnings for FY 2018, with revenues at only RMB 934,000, down 18.64% year-on-year (YOY) and net profits at a negative minus RMB 716 million, down 123.11% YOY.
A Sino-US team of researchers have reported developing a new improved chimeric antigen receptor (CAR) T cell therapy, according to a study published in Nature Medicine.
  • 1556168634038
  • China
  • R&D
China-based Viva Biotech Holdings (1873.HK) announced an initial public offering (IPO) of 345,000,000 shares with price ranging from HKD 3.42 to HKD 4.41 per share.
Switzerland-based ADC Therapeutics and the China-based Adagene announced a discovery partnership and licensing deal focused on the development of next-generation masked antibody drug conjugates (ADCs).
U.S.-based Boston Children's Hospital (BCH) and Sino-US high-end clinics operator and healthcare service provider MORE Health Inc., announced a strategic partnership that will allow Chinese patients to access BCH's physicians for diagnosis and treatment.
China’s National Medical Products Administration (NMPA) released the medical devices awarded market approval during March 2019.
Analytics Snapshot


The news, data, tools, and insights you need to make the best decisions.